Related Experiment Video
Updated: Jul 1, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
Published on: March 17, 2019
Pharmacotherapy of irritability in pervasive developmental disorders
Kimberly A Stigler1, Christopher J McDougle
1Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202-5200, USA. kstigler@uipui.edu
Abstract:
Children and adolescents diagnosed with autism and related pervasive developmental disorders (PDDs) often sustain irritability, including aggression, self-injurious behavior, and tantrums. Research to date supports the use of the atypical antipsychotics as a first-line pharmacologic treatment for this target symptom domain in PDDs. Currently, the atypical antipsychotic risperidone is the only medication approved by the US Food and Drug Administration for irritability in youth with autism. Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group.
Related Concept Videos
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Oppositional Defiant Disorder
Diagnostic Criteria and...